RxDoctor Payments Data

Scott Macleod, DO

General Practice · Las Vegas, NVNPI 1841359700

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.1% of the total across 341 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by AbbVie at 28.9% of the total. Among general practice clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,904in general payments, 2019–2025

Across 341 payments — averaging $26.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$999
  • LEO Pharma Inc.$664
  • Galderma Laboratories, L.p.$579
  • Dermavant Sciences, Inc.$470
  • Sanofi$463
  • plus $3K from 26 others

What the payments were for

  • Food & beverage$8,55896%
  • Education$3464%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,904 in reported general payments places this provider in the 95th percentile of 910 general practice providers in Nevada.

See all general practice providers in Nevada

Medicare billing

Part B allowed, 2024
$102,163
Medicare patients
212
Services billed
659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clobetasol Propionate30$1,579
Imiquimod31$873
Tacrolimus15$839
Doxycycline Hyclate26$631
Fluocinonide14$442
Ketoconazole33$416
Mupirocin35$247

Paid to pharmacies, not to this prescriber.

Other general practice in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →